Esperion Therapeutics

Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Esperion Therapeutics reports robust Q4 earnings, eyes global expansion

Esperion Therapeutics delivered strong financial results in Q4 2022, driven by successful formulary additions and international partner growth.
The company faces challenges in increasing brand awareness and effectively positioning bempedoic acid post statins, requiring strategic marketing and market access initiatives.
Opportunities lie in leveraging upcoming trial results for label expansion, enhancing brand visibility, and capitalizing on international growth through partnerships.

Esperion Therapeutics excels in Q1 2023, poised for market opportunities

Esperion Therapeutics delivered robust Q1 results with revenue growth and positive market reactions to its studies. While facing legal challenges and operational discussions, the company is well-positioned to leverage opportunities in the market through its strong partnerships and financial stability.

Esperion Therapeutics excels in Q2 earnings, eyes label expansion opportunities

Esperion Therapeutics delivered strong financial performance in Q2 2023, driven by revenue growth, cost management, and strategic partnerships.
While facing challenges in managing expenses, the company is well-positioned to capitalize on market opportunities post-label expansion approvals.
With a solid cash position, ongoing operational efficiency efforts, and a focus on growth initiatives, Esperion is poised for continued success.
The company's commitment to innovation and patient outcomes bodes well for its future growth trajectory and market competitiveness.

Esperion Therapeutics excels in Q3 earnings amidst regulatory hurdles

Esperion Therapeutics delivered strong financial results in Q3 2023, driven by revenue growth and strategic collaborations, despite facing regulatory and litigation challenges.
The company's focus on expanding market presence through FDA approvals and international expansion presents promising growth avenues for future success.
With a solid financial position and ongoing initiatives to drive prescription growth, Esperion is poised to capitalize on market opportunities and navigate challenges effectively.

Esperion Therapeutics reports robust Q4 earnings and eyes market expansion

Esperion Therapeutics delivered strong financial performance in Q4 2023, showcasing significant revenue growth and strategic advancements.
While facing challenges in managing expenses and executing growth strategies, the company is well-positioned to capitalize on market opportunities and drive future expansion.
With a clear roadmap for expense management and a focus on product reach and market expansion, Esperion is poised for continued growth and value creation for stakeholders.
The settlement agreement and label expansion approvals provide a solid foundation for Esperion to leverage opportunities, overcome challenges, and drive sustainable growth.

Esperion Therapeutics posts robust Q1 results amid FDA label wins

Esperion Therapeutics delivered strong financial performance in Q1 2024, driven by revenue growth and FDA label expansions.
The company faces challenges in maintaining prescription growth and navigating payer dynamics post-label update.
Strategic initiatives and market opportunities present avenues for Esperion to capitalize on its recent successes and drive future growth.

Esperion Therapeutics reports robust Q2 revenue growth and global expansion

Esperion Therapeutics delivered strong financial performance in Q2 2024, driven by revenue growth and successful market expansion efforts.
While facing challenges such as debt extinguishment losses and high operating expenses, the company capitalized on opportunities for international growth and product marketability.
By leveraging strengths in expanded product labels and improved market access, Esperion is poised to navigate challenges and capitalize on growth opportunities in the pharmaceutical sector.

Esperion Therapeutics reports robust Q3 performance and eyes global expansion

Esperion Therapeutics delivered strong financial performance in Q3 2024, driven by revenue growth and strategic initiatives to expand market access and product offerings.
While challenges in achieving profitability persist, the company's focus on innovation, global expansion, and operational efficiency underscores its long-term growth potential.
By leveraging strengths in collaboration, research, and market differentiation, Esperion is poised to capitalize on opportunities for further international expansion and brand recognition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

– Positive CLEAR Outcomes data to be presented as a Late-Breaking Clinical Trial (LBCT) at ACC.23/WCC on March 4, 2023 –

CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)

Here is how Esperion Therapeutics (ESPR) and TransMedics (TMDX) have performed compared to their sector so far this year.

Is Esperion Therapeutics (ESPR) Outperforming Other Medical Stocks This Year?

Esperion (ESPR) announces positive data from the CLEAR Outcomes study, which further strengthens the clinical evidence supporting the role of bempedoic acid for patients and will boost the growth potential of the drug.

Esperion (ESPR) Reports Positive Data From CLEAR Study

Prometheus Biosciences

At least two biotech stocks are triggering an options trading frenzy today, with Prometheus Biosciences Inc (NASDAQ:RXDX) and Esperion Therapeutics Inc (NASDAQ:ESPR) moving in opposite directions following their respective drug updates.

2 Biotech Stocks Options Traders Love Today

– Demonstrates statistically significant and clinically meaningful results –

Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

Why Is Esperion Therapeutics (ESPR) Down 16.7% Since Last Earnings Report?

ANN ARBOR, Mich., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Ben Halladay, MBA, has been promoted to the role of Chief Financial Officer (CFO) from his prior position of Senior Director, Financial Planning and Analysis, effective as of today. He will serve as a member of the executive management team and report to Sheldon Koenig, President and Chief Executive Officer.

Esperion Appoints Ben Halladay Chief Financial Officer

Esperion Therapeutics reported its Q3 earnings with a beat on EPS and a slight miss on revenue. The company was able to report significant revenue growth and encouraging commercial trends. The highly anticipated CLEAR Outcomes data is expected to be announced in January. I anticipate increased volatility before and after the data readout.

Esperion Therapeutics: Q3 Earnings Reveal Progress Ahead Of CLEAR Outcomes Data

– Event to Include Expert-Led Discussions on State of Cardiovascular Disease Treatments and Remaining Unmet Needs –

Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus

The consensus price target hints at a 32.5% upside potential for Esperion Therapeutics (ESPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Esperion Therapeutics (ESPR) Could Surge 32%: Read This Before Placing a Bet

Esperion Therapeutics (ESPR) reports mixed third-quarter results, beating earnings estimates but missing out on sales.

Esperion (ESPR) Q3 Earnings Beat Estimates, Revenues Miss

Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q3 2022 Earnings Conference Call November 1, 2022 8:00 AM ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koenig - President & Chief Executive Officer JoAnne Foody - Chief Medical Officer Eric Warren - Chief Commercial Officer Benjamin Halladay - Senior Director of Finance Conference Call Participants Mike Yee - Jefferies Serge Belanger - Needham & Company Tom Shrader - BTIG Mike Riad - Morgan Stanley Joseph Thome - Cowen Jason Butler - JMP Securities Judah Frommer - Credit Suisse Paul Choi - Goldman Sachs Operator Ladies and gentlemen, thank you for standing by and welcome. [Operator Instructions] Please be advised that today's conference call may be recorded.

Esperion Therapeutics, Inc. (ESPR) Q3 2022 Earnings Call Transcript

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.90% and 4.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics (ESPR) Reports Q3 Loss, Misses Revenue Estimates

– CLEAR Outcomes Trial Achieved Last Patient Last Visit in October Ensuring Timely Trial Completion –

Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update

ANN ARBOR, Mich., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2022 financial results before the open of the U.S. financial markets on Tuesday, November 1st, 2022.

Esperion to Report Third Quarter 2022 Financial Results November 1, 2022

Esperion Therapeutics (ESPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Esperion Therapeutics (ESPR) Moves 6.5% Higher: Will This Strength Last?

Esperion Therapeutics (ESPR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Esperion Therapeutics (ESPR): Can Its 5.7% Jump Turn into More Strength?

Esperion Therapeutics (ESPR) Up 29.3% Since Last Earnings Report: Can It Continue?

ANN ARBOR, Mich., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that bempedoic acid (NEXLETOL®) is now recommended as an important oral non-statin therapy for LDL-cholesterol (LDL-C) lowering in the management of atherosclerotic cardiovascular disease (ASCVD) by the American College of Cardiology (ACC) task force on expert consensus decision pathways (ECDP). The recommendation, an update to the 2017 ECDP, was released on August 25, 2022 and published online in the Journal of the American College of Cardiology.

Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway

Esperion Therapeutics reported its Q2 earnings that revealed a beat on revenue, but a miss on EPS. However, the company announced that it has hit 100% MACE-4 accumulation. The company's mixed earnings were only a slight improvement over Q1. I was expecting the market to punish ESPR, but it appears the possibility of a Q1 readout offset.

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Esperion Therapeutics (ESPR) reports dismal second-quarter results, missing estimates for earnings and sales. However, shares rose on the back of ESPR's progress with its cardiovascular outcome study.

Esperion (ESPR) Q2 Earnings and Revenues Miss Estimates

Start Time: 08:00 January 1, 0000 8:44 AM ET Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q2 2022 Earnings Conference Call August 02, 2022, 08:00 AM ET Company Participants Sheldon Koenig - President and CEO JoAnne Foody - CMO Eric Warren - Chief Commercial Officer BJ Swartz - Chief Strategy Officer Tiffany Aldrich - Senior Manager, Corporate Communications Conference Call Participants Joseph Thome - Cowen Michael Riad - Morgan Stanley Michael Yee - Jefferies Jessica Fye - JPMorgan Judah Frommer - Credit Suisse Serge Belanger - Needham & Company Jason Butler - JMP Securities Paul Choi - Goldman Sachs Operator Ladies and gentlemen, thank you for standing by and welcome. At this time, all participants are in a listen-only mode.

Esperion Therapeutics, Inc. (ESPR) CEO Sheldon Koenig on Q2 2022 Results - Earnings Call Transcript

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -10.53% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics (ESPR) Reports Q2 Loss, Misses Revenue Estimates

– Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial; On Track for Topline Results 1Q 2023 –

Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update

ANN ARBOR, Mich., July 25, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the establishment of its Scientific Advisory Board (SAB). The inaugural members of the Esperion SAB represent a diverse group of internationally renowned experts who will bring a depth and breadth of basic, translational, and clinical research experience across several key therapeutic areas that will inform our research and development strategy moving forward. The members of the SAB are at the forefront of research in atherosclerosis and atherosclerotic cardiovascular disease, inflammation, metabolic disorders, and non-alcoholic steatohepatitis/non-alcoholic fatty liver disease.

News for Esperion Therapeutics Stock (ESPR)